Literature DB >> 20093560

LOX index, a novel predictive biochemical marker for coronary heart disease and stroke.

Nobutaka Inoue1, Tomonori Okamura, Yoshihiro Kokubo, Yoshiko Fujita, Yuko Sato, Mamoru Nakanishi, Kazuki Yanagida, Akemi Kakino, Shin Iwamoto, Makoto Watanabe, Sayoko Ogura, Kazunori Otsui, Haruo Matsuda, Kagehiro Uchida, Ryo Yoshimoto, Tatsuya Sawamura.   

Abstract

BACKGROUND: Lectin-like oxidized LDL receptor 1 (LOX-1) is implicated in atherothrombotic diseases. Activation of LOX-1 in humans can be evaluated by use of the LOX index, obtained by multiplying the circulating concentration of LOX-1 ligands containing apolipoprotein B (LAB) times that of the soluble form of LOX-1 (sLOX-1) [LOX index = LAB x sLOX-1]. This study aimed to establish the prognostic value of the LOX index for coronary heart disease (CHD) and stroke in a community-based cohort.
METHODS: An 11-year cohort study of 2437 residents age 30-79 years was performed in an urban area located in Japan. Of these, we included in the analysis 1094 men and 1201 women without history of stroke and CHD. We measured LAB and sLOX-1 using ELISAs with recombinant LOX-1 and monoclonal anti-apolipoprotein B antibody and with 2 monoclonal antibodies against LOX-1, respectively.
RESULTS: During the follow-up period, there were 68 incident cases of CHD and 91 cases of stroke (with 60 ischemic strokes). Compared with the bottom quartile, the hazard ratio (HR) of the top quartile of LOX index was 1.74 (95% CI 0.92-3.30) for stroke and 2.09 (1.00-4.35) for CHD after adjusting for sex, age, body mass index, drinking, smoking, hypertension, diabetes, non-HDL cholesterol, and use of lipid-lowering agents. Compared with the bottom quartile of LOX index, the fully adjusted HRs for ischemic stroke were consistently high from the second to the top quartile: 3.39 (95% CI 1.34-8.53), 3.15 (1.22-8.13) and 3.23 (1.24-8.37), respectively.
CONCLUSIONS: Higher LOX index values were associated with an increased risk of CHD. Low LOX index values may be protective against ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20093560     DOI: 10.1373/clinchem.2009.140707

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  42 in total

Review 1.  LOX-1, a new marker of risk and prognosis in coronary artery disease?

Authors:  Valter Lubrano; Silvana Balzan
Journal:  Mol Cell Biochem       Date:  2013-08-11       Impact factor: 3.396

Review 2.  An integrated approach to coronary heart disease diagnosis and clinical management.

Authors:  Teresa Infante; Ernesto Forte; Concetta Schiano; Carlo Cavaliere; Carlo Tedeschi; Andrea Soricelli; Marco Salvatore; Claudio Napoli
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

3.  Pitavastatin reduces lectin-like oxidized low-density lipoprotein receptor-1 ligands in hypercholesterolemic humans.

Authors:  Tetsuya Matsumoto; Masatoshi Fujita; Tatsuya Sawamura; Akemi Kakino; Yuko Sato; Yoshiko Fujita; Haruo Matsuda; Mamoru Nakanishi; Kagehiro Uchida; Izuru Nakae; Hiroshi Kanda; Akira Yoshida; Kunihisa Miwa; Hideki Hayashi; Kenichi Mitsunami; Minoru Horie
Journal:  Lipids       Date:  2010-03-13       Impact factor: 1.880

Review 4.  Consolidated and emerging inflammatory markers in coronary artery disease.

Authors:  Valter Lubrano; Silvana Balzan
Journal:  World J Exp Med       Date:  2015-02-20

5.  Circulating oxidized LDL, increased in patients with acute myocardial infarction, is accompanied by heavily modified HDL.

Authors:  Naoko Sawada; Takashi Obama; Shinji Koba; Takashi Takaki; Sanju Iwamoto; Toshihiro Aiuchi; Rina Kato; Masaki Kikuchi; Yuji Hamazaki; Hiroyuki Itabe
Journal:  J Lipid Res       Date:  2020-04-14       Impact factor: 5.922

6.  LOX-1 ligands containing apolipoprotein B and carotid intima-media thickness in middle-aged community-dwelling US Caucasian and Japanese men.

Authors:  Tomonori Okamura; Akira Sekikawa; Tatsuya Sawamura; Takashi Kadowaki; Emma Barinas-Mitchell; Rachel H Mackey; Aya Kadota; Rhobert W Evans; Daniel Edmundowicz; Aya Higashiyama; Yasuyuki Nakamura; Robert D Abbott; Katsuyuki Miura; Akira Fujiyoshi; Yoshiko Fujita; Yoshitaka Murakami; Naomi Miyamatsu; Akemi Kakino; Hiroshi Maegawa; Kiyoshi Murata; Minoru Horie; Kenichi Mitsunami; Atsunori Kashiwagi; Lewis H Kuller; Hirotsugu Ueshima
Journal:  Atherosclerosis       Date:  2013-04-30       Impact factor: 5.162

Review 7.  LOX-1 in atherosclerosis: biological functions and pharmacological modifiers.

Authors:  Suowen Xu; Sayoko Ogura; Jiawei Chen; Peter J Little; Joel Moss; Peiqing Liu
Journal:  Cell Mol Life Sci       Date:  2012-11-03       Impact factor: 9.261

8.  Relationships of oxidized HDL with blood coagulation and fibrinolysis in patients with type 2 diabetes mellitus.

Authors:  Shigeyuki Ebara; Mikio Marumo; Jun Mukai; Makoto Ohki; Kagehiro Uchida; Ichiro Wakabayashi
Journal:  J Thromb Thrombolysis       Date:  2018-02       Impact factor: 2.300

9.  Lectin-like oxidized low-density lipoprotein receptor (LOX-1) in sickle cell disease vasculopathy.

Authors:  Mingyi Chen; Hong Qiu; Xin Lin; David Nam; Lucy Ogbu-Nwobodo; Hannah Archibald; Amelia Joslin; Ted Wun; Tatsuya Sawamura; Ralph Green
Journal:  Blood Cells Mol Dis       Date:  2016-06-25       Impact factor: 3.039

10.  123I-Labeled oxLDL Is Widely Distributed Throughout the Whole Body in Mice.

Authors:  Atushi Nakano; Hidekazu Kawashima; Yoshinori Miyake; Tsutomu Zeniya; Akihide Yamamoto; Kazuhiro Koshino; Takashi Temma; Tetsuya Fukuda; Yoshiko Fujita; Akemi Kakino; Shigehiko Kanaya; Tatsuya Sawamura; Hidehiro Iida
Journal:  Nucl Med Mol Imaging       Date:  2017-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.